-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HNSaIFv/Ly/i8qA+9/GzLqnfMrUyHBcdhxYL7eG8OVbxLmeezuAJDBSqFchTPEY0 HlT8IYgU4+Jg7YnOs7YSCg== 0001362310-07-000234.txt : 20070307 0001362310-07-000234.hdr.sgml : 20070307 20070307164042 ACCESSION NUMBER: 0001362310-07-000234 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070301 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20070307 DATE AS OF CHANGE: 20070307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTHWEST BIOTHERAPEUTICS INC CENTRAL INDEX KEY: 0001072379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943306718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33393 FILM NUMBER: 07678253 BUSINESS ADDRESS: STREET 1: 18701 120TH AVENUE NE STREET 2: SUITE 100 CITY: BOTHELL STATE: WA ZIP: 98011 BUSINESS PHONE: 4256083008 MAIL ADDRESS: STREET 1: 18701 120TH AVENUE NE STREET 2: SUITE 100 CITY: BOTHELL STATE: WA ZIP: 98011 8-K 1 c70255e8vk.htm FORM 8-K e8vk
 

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 1, 2007

NORTHWEST BIOTHERAPEUTICS, INC.
 (Exact name of registrant as specified in its charter)
         
DELAWARE   0-33393   94-3306718
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
18701 120th Avenue NE, Suite 101, Bothell, WA
  98011
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (425) 608-3000
 
INAPPLICABLE
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1

 

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Effective March 1, 2007, Northwest Biotherapeutics, Inc., a Delaware corporation (the “Company”), named Jim Johnston, Chief Financial Officer and General Counsel. During the past five years, Mr. Johnston has operated a law practice located in Bellevue, Washington and acted as outside legal counsel to the Company. He has also previously served as Chief Financial Officer and/or General Counsel to both public and private businesses.

 

2

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 7, 2007

NORTHWEST BIOTHERAPEUTICS, INC.
 
By /s/ Alton Boynton                                           
Alton L. Boynton
President

 

3

-----END PRIVACY-ENHANCED MESSAGE-----